Nichol Miller

发表

Title Analyses of merlin / NF 2 connection to FAK inhibitor responsiveness in serous ovarian cancer

D. Schlaepfer, C. Jean, N. Miller, 2014 .

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.

X. Mu, J. Bienkowska, Zhou Zhu, 2021, Cancer cell.

Marjory L. Givens, N. Miller, P. Mellon, 2005, Journal of Biological Chemistry.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.

J. Lapek, Sherry L. Niessen, M. McTigue, 2021, Journal of medicinal chemistry.

Necdin, a Prader-Willi syndrome candidate gene, regulates gonadotropin-releasing hormone neurons during development.

R. Wevrick, N. Miller, P. Mellon, 2008, Human molecular genetics.

Gastrin-stimulated Gα13 Activation of Rgnef Protein (ArhGEF28) in DLD-1 Colon Carcinoma Cells*

D. Schlaepfer, N. Miller, L. Pérez-Benito, 2015, The Journal of Biological Chemistry.

RhoGEFs in cell motility: novel links between Rgnef and focal adhesion kinase.

D. Schlaepfer, N. Miller, E. Kleinschmidt, 2014, Current molecular medicine.

Rgnef (p190RhoGEF) Knockout Inhibits RhoA Activity, Focal Adhesion Establishment, and Cell Motility Downstream of Integrins

S. Lim, D. Schlaepfer, N. Miller, 2012, PloS one.

Knock-in Mutation Reveals an Essential Role for Focal Adhesion Kinase Activity in Blood Vessel Morphogenesis and Cell Motility-Polarity but Not Cell Proliferation*

S. Lim, Xiao Lei Chen, D. Schlaepfer, 2010, The Journal of Biological Chemistry.

Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance

N. Miller, B. Murray, B. Murray, 2015, Molecular Cancer Therapeutics.

Rgnef promotes ovarian tumor progression and confers protection from oxidative stress

D. Schlaepfer, D. Stupack, N. Miller, 2019, Oncogene.

Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.

S. Kaiser, M. Kraus, A. Stewart, 2017, Journal of medicinal chemistry.

Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function

E. Dejana, Xiao Lei Chen, D. Schlaepfer, 2014, The Journal of cell biology.

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

C. Dillon, Xianxian Zheng, M. Kraus, 2018, Molecular Cancer Therapeutics.

Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.

D. Schlaepfer, C. Jean, N. Miller, 2014, Gynecologic oncology.

A non-canonical role for Rgnef in promoting integrin-stimulated focal adhesion kinase activation

D. Schlaepfer, N. Miller, S. Uryu, 2013, Journal of Cell Science.

Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression

D. Tarin, D. Schlaepfer, C. Jean, 2013, Clinical & Experimental Metastasis.

Hypothalamic Dysregulation and Infertility in Mice Lacking the Homeodomain Protein Six6

N. Miller, P. Mellon, R. Larder, 2011, The Journal of Neuroscience.

p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.

S. Lim, D. Schlaepfer, Hong-gang Yu, 2011, Cancer research.

Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression

S. Lim, Xiao Lei Chen, D. Schlaepfer, 2012, The Journal of cell biology.

kinase regulates expression.

S. Lim, D. Schlaepfer, D. Cheresh, 2012 .

Enhancers of GnRH transcription embedded in an upstream gene use homeodomain proteins to specify hypothalamic expression.

A. Iyer, N. Miller, Kathleen Yip, 2010, Molecular endocrinology.

Homeodomain Proteins to Specify Hypothalamic Expression Enhancers of GnRH Transcription Embedded in an Upstream Gene Use

Kathleen Yip, B. Tran, P. Mellon, 2010 .

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

Paolo Vicini, Deepak Dalvie, Chad Ray, 2016 .

Phylogenetic footprinting reveals evolutionarily conserved regions of the gonadotropin-releasing hormone gene that enhance cell-specific expression.

Marjory L. Givens, N. Miller, P. Mellon, 2004, Molecular endocrinology.

FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

D. Schlaepfer, C. Jean, N. Miller, 2014, Molecular Cancer Therapeutics.

The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models.

E. Martin, Eric A. Murphy, P. Severson, 2021 .

FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth

D. Schlaepfer, C. Jean, N. Miller, 2015, Breast Cancer Research.

Pyk2 Inhibition of p53 as an Adaptive and Intrinsic Mechanism Facilitating Cell Proliferation and Survival*

S. Lim, Y. Lim, D. Schlaepfer, 2009, The Journal of Biological Chemistry.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Rgnef promotes ovarian tumor progression and confers protection from oxidative stress

D. Schlaepfer, D. Stupack, D. Connolly, 2019, Oncogene.

Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity

S. Spencer, M. Barbacid, J. Lapek, 2023, Cell.

RhoGEF ( Rgnef ) Promotes Colon Carcinoma Tumor Progression via Interaction with Focal Adhesion Kinase

S. Lim, D. Schlaepfer, Hong-gang Yu, 2011 .

Enhancers of GnRH transcription embedded in an upstream gene use homeodomain proteins to specify hypothalamic expression.

Kathleen Yip, B. Tran, P. Mellon, 2010, Molecular endocrinology.